Publications by authors named "W Badowska"

Background: A personalised approach to the treatment of acute myeloid leukemia (AML) in children and adolescents, as well as the development of supportive therapies, has significantly improved survival. Despite this, some patients still die before starting treatment or in an early phase of therapy before achieving remission. The study analysed the frequency, clinical features and risk factors for early deaths (ED) and treatment related deaths (TRD) of children and adolescents with AML.

View Article and Find Full Text PDF

is a nosocomial pathogen that causes severe infections in immunocompromised patients. The aim of the study was to conduct a microbiological and clinical analysis of infections in children with malignancies or undergoing hematopoietic cell transplantation in Poland. We conducted a retrospective, multicenter study including children and adolescents under 19 years old treated between 2012 and 2021.

View Article and Find Full Text PDF

Background: The reports of studies that compare the survival of adolescents and young adults with younger children with acute myeloid leukemia (AML) are contradictory.

Patients And Methods: We retrospectively analyzed 220 AML patients aged 0-18 years treated in pediatric oncologic centers in Poland from 2015 to 2022. The evaluated group included 31 infants (below 1 year), 91 younger children (1-9.

View Article and Find Full Text PDF

The most common complications related to the treatment of childhood acute lymphoblastic leukemia (ALL) are infections. The aim of the study was to analyze the incidence and mortality rates among pediatric patients with ALL who were treated in 17 Polish pediatric hematology centers in 2020-2021 during the pandemic. Additionally, we compared these results with those of our previous study, which we conducted in the years 2012-2017.

View Article and Find Full Text PDF
Article Synopsis
  • The FLT3 gene mutation occurs in 10-15% of pediatric acute myeloid leukemia (AML) cases and is linked to poorer outcomes in patients.
  • A study analyzed data from 2005 to 2022, revealing that FLT3-ITD-positive patients had significantly lower survival rates compared to those without the mutation.
  • Results indicated that treatment advancements, like FLT3 inhibitors and stem cell transplants, improved survival rates, while additional genetic mutations (WT1 and NPM1) impacted prognosis significantly.
View Article and Find Full Text PDF